In a 4T1 mouse model of triple negative breast cancer (TNBC), TVN was achievedfollowing a treatment with a novel integrin-binding peptide.This treatment reduced the overall PD-L1 expression in the tumor including the PD-L1 expression on TAMs [77]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.